171 related articles for article (PubMed ID: 23031740)
41. A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome suspected families.
Llovet P; Illana FJ; Martín-Morales L; de la Hoya M; Garre P; Ibañez-Royo MD; Pérez-Segura P; Caldés T; García-Barberán V
Fam Cancer; 2017 Oct; 16(4):567-575. PubMed ID: 28573494
[TBL] [Abstract][Full Text] [Related]
42. p53 Germline mutation in a patient with Li-Fraumeni Syndrome and three metachronous malignancies.
Pötzsch C; Voigtländer T; Lübbert M
J Cancer Res Clin Oncol; 2002 Aug; 128(8):456-60. PubMed ID: 12200603
[TBL] [Abstract][Full Text] [Related]
43. [A rhabdomyosarcoma patient from a Li-Fraumeni syndrome family: a case report and literature review].
Xie Y; Zhao WH; Hua Y; Sun Q; Wu PH
Zhongguo Dang Dai Er Ke Za Zhi; 2017 Dec; 19(12):1263-1266. PubMed ID: 29237527
[TBL] [Abstract][Full Text] [Related]
44. Successful Treatment of Recurrent Li-Fraumeni Syndrome-related Choroid Plexus Carcinoma.
McEvoy M; Robison N; Manley P; Yock T; Konopka K; Brown RE; Wolff J; Green AL
J Pediatr Hematol Oncol; 2017 Nov; 39(8):e473-e475. PubMed ID: 28859040
[TBL] [Abstract][Full Text] [Related]
45. CD82 suppresses CD44 alternative splicing-dependent melanoma metastasis by mediating U2AF2 ubiquitination and degradation.
Zhang P; Feng S; Liu G; Wang H; Fu A; Zhu H; Ren Q; Wang B; Xu X; Bai H; Dong C
Oncogene; 2016 Sep; 35(38):5056-5069. PubMed ID: 27041584
[TBL] [Abstract][Full Text] [Related]
46. Pediatric cancer and Li-Fraumeni/Li-Fraumeni-like syndromes: a review for the pediatrician.
Giacomazzi CR; Giacomazzi J; Netto CB; Santos-Silva P; Selistre SG; Maia AL; Oliveira VZ; Camey SA; Goldim JR; Ashton-Prolla P
Rev Assoc Med Bras (1992); 2015; 61(3):282-9. PubMed ID: 26248253
[TBL] [Abstract][Full Text] [Related]
47. Analysis of Li-Fraumeni syndrome and Li-Fraumeni-like families for germline mutations in Bcl10.
Stone JG; Eeles RA; Sodha N; Murday V; Sheriden E; Houlston RS
Cancer Lett; 1999 Dec; 147(1-2):181-5. PubMed ID: 10660104
[TBL] [Abstract][Full Text] [Related]
48. Germline mutations of the p53 tumor-suppressor gene in cancer-prone families: a review.
Soussi T; Leblanc T; Baruchel A; Schaison G
Nouv Rev Fr Hematol (1978); 1993 Feb; 35(1):33-6. PubMed ID: 8511038
[TBL] [Abstract][Full Text] [Related]
49. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
[TBL] [Abstract][Full Text] [Related]
50. Germline p53 mutation in a case of Li-Fraumeni syndrome presenting gastric cancer.
Sugano K; Taniguchi T; Saeki M; Tsunematsu Y; Tomaru U; Shimoda T
Jpn J Clin Oncol; 1999 Oct; 29(10):513-6. PubMed ID: 10645809
[No Abstract] [Full Text] [Related]
51. Association between Predicted Effects of
Liu Y; Axell O; van Leeuwen T; Konrat R; Kharaziha P; Larsson C; Wright APH; Bajalica-Lagercrantz S
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34198491
[TBL] [Abstract][Full Text] [Related]
52. Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.
Ferreira AM; Brondani VB; Helena VP; Charchar HLS; Zerbini MCN; Leite LAS; Hoff AO; Latronico AC; Mendonca BB; Diz MDPE; de Almeida MQ; Fragoso MCBV
J Steroid Biochem Mol Biol; 2019 Jun; 190():250-255. PubMed ID: 30974190
[TBL] [Abstract][Full Text] [Related]
53. Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.
Zhou R; Xu A; Gingold J; Strong LC; Zhao R; Lee DF
Trends Pharmacol Sci; 2017 Oct; 38(10):908-927. PubMed ID: 28818333
[TBL] [Abstract][Full Text] [Related]
54. Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with Li-Fraumeni syndrome.
Henry E; Villalobos V; Million L; Jensen KC; West R; Ganjoo K; Lebensohn A; Ford JM; Telli ML
J Natl Compr Canc Netw; 2012 Aug; 10(8):939-42. PubMed ID: 22878818
[TBL] [Abstract][Full Text] [Related]
55. Astrocytoma and B-cell lymphoma development in a man with a p53 germline mutation.
Murakawa Y; Yokoyama A; Kato S; Yoshioka T; Ichinohasama R; Kumabe T; Yoshimoto T; Ishioka C; Kanamaru R
Jpn J Clin Oncol; 1998 Oct; 28(10):631-7. PubMed ID: 9839505
[TBL] [Abstract][Full Text] [Related]
56. The v8-10 variant isoform of CD44 is selectively expressed in the normal human colonic stem cell niche and frequently is overexpressed in colon carcinomas during tumor development.
Boman BM; Viswanathan V; Facey COB; Fields JZ; Stave JW
Cancer Biol Ther; 2023 Dec; 24(1):2195363. PubMed ID: 37005380
[TBL] [Abstract][Full Text] [Related]
57. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
[TBL] [Abstract][Full Text] [Related]
58. Super-Transactivation TP53 Variant in the Germline of a Family with Li-Fraumeni Syndrome.
Id Said B; Kim H; Tran J; Novokmet A; Malkin D
Hum Mutat; 2016 Sep; 37(9):889-92. PubMed ID: 27297285
[TBL] [Abstract][Full Text] [Related]
59. EFGR-mutant lung adenocarcinoma and Li-Fraumeni syndrome: report of two cases and review of the literature.
Ricordel C; Labalette-Tiercin M; Lespagnol A; Kerjouan M; Dugast C; Mosser J; Desrues B; Léna H
Lung Cancer; 2015 Jan; 87(1):80-4. PubMed ID: 25433984
[TBL] [Abstract][Full Text] [Related]
60. Prenatal diagnosis in Li-Fraumeni syndrome.
Avigad S; Peleg D; Barel D; Benyaminy H; Ben-Baruch N; Taub E; Shohat M; Goshen Y; Cohen IJ; Yaniv I; Zaizov R
J Pediatr Hematol Oncol; 2004 Sep; 26(9):541-5. PubMed ID: 15342977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
